With respect to BMP5 , we observed a decreasing trend in mean expression from baseline to six months in natalizumab-treated patients versus an increasing trend in non–natalizumab-treated patients.
← all excerpts
Changes in the Expression of TGF-Beta Regulatory Pathway Genes Induced by Vitamin D in Patients with Relapsing-Remitting Multiple Sclerosis.
1
—
—